EFFECTIVE AUGUST 27, Nasdaq Stock Market, Inc. delisted the stock of IMPATH, Inc. Less than a week earlier, IMPATH had disclosed that it was under investigation by the Securities and Exchange Commission (SEC). IMPATH can truly be described as a company under siege. It is short of cash, under regulatory investigation, and defending itself from […]
- "The Dark Index"
IMPATH Delisted by Nasdaq, Under Investigation by SEC
Onetime high-flying pathology company now faces incredible scrutiny on almost all fronts
- By Robert Michel
- > From the Volume X No. 12 - September 8, 2003 Issue
